Lombard Medical Technologies PLC Registration statement filed ahead of proposed IPO (9665B)

TIDMLMT

RNS Number : 9665B

Lombard Medical Technologies PLC

11 March 2014

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Lombard Medical, Inc. files registration statement with SEC

ahead of proposed IPO on NASDAQ Global Market

London, UK and Irvine, CA, 11 March, 2014 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic aneurysms ("AAAs"), announced today that Lombard Medical, Inc. has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not yet been determined.

The Company has reserved the ticker "EVAR" for its listing on the NASDAQ Global Market. In connection with the NASDAQ listing, Lombard Medical will also delist its ordinary shares from AIM, a market of the London Stock Exchange and complete a change of domicile, with Lombard Medical, Inc., a Cayman Islands corporation, becoming the holding company for the group.

Lombard Medical intends to use proceeds from the proposed NASDAQ offering to expand its direct sales force in the United States and develop new products to treat complex vascular disease, including a stent graft to treat aneurysms in the thoracic aorta. The remaining proceeds will be used for working capital and for general corporate purposes.

Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers or the proposed offering, and BTIG, LLC is acting as co-manager.

The proposed offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, by email at Prospectus_Department@Jefferies.com, by phone at 877-547-6340 or by mail at 520 Madison Avenue, 2nd Floor, New York, NY 10022 or Barclays Capital Inc., c/o Broadridge Financial Solutions, by email at Barclaysprospectus@broadridge.com, by phone at 888-603-5847 or by mail at 1155 Long Island Avenue, Edgewood, NY 11717.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there by any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

-Ends-

For further information:

 
 Lombard Medical Technologies PLC       Tel: +44 (0)1235 750 800 
  Simon Hubbert, Chief Executive 
  Officer 
  Ian Ardill, Chief Financial Officer 
 
 Canaccord Genuity Limited (Nomad)      Tel: +44 (0)20 7523 8350 
  Lucy Tilley / Henry Fitzgerald 
  O'Connor / Dr Julian Feneley 
 
 FTI Consulting (UK)                    Tel: +44 (0)20 7831 3113 
  Simon Conway / Stephanie Cuthbert 
  / Victoria Foster Mitchell 
 
 Life Capital Partners, LLC (US)          Tel: +1 (949) 370-8500 
  Matt Clawson

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company focused on device solutions for the $1.4 billion per annum abdominal aortic aneurysm ("AAA") repair market. The Company's lead product, Aorfix, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. The Company is headquartered in Oxfordshire, England with US operations in Irvine, CA.

FORWARD-LOOKING STATEMENTS

This announcement may contain forward-looking statements that reflect the Company's current expectations regarding future events, including the commercialization and regulatory clearance of the Company's products, the Group's liquidity and results of operations, as well as the Group's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's research and development and commercialization strategies, the uncertainties related to the regulatory process and the acceptance of the Company's products by hospitals and other medical professionals.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCJMMTTMBIBTRI

Lombard Medical Technologies (LSE:LMT)
過去株価チャート
から 11 2024 まで 12 2024